Save the date: Implantica Capital Markets Day 2023
Comunicato Precedente
Comunicato Successivo
More information will be made available at a later stage.
For further information, please contact:
Nicole Pehrsson, Chief Corporate Affairs Officer
Telephone (CH): +41 (0)79 335 09 49
nicole.pehrsson@implantica.com
Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm.
The company's Certified Adviser is FNCA Sweden AB, info@fnca.se
The information was sent for publication, through the agency of the contact person set out above, on August 21, 2023, at 8:00 a.m. CEST.
About Implantica
Implantica is a medtech group dedicated to bringing advanced technology into the body. Implantica's lead product, RefluxStop™, is a CE-marked implant for the prevention of gastroesophageal reflux that will potentially create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results. Implantica also focuses on eHealth inside the body and has developed a broad, patent protected, product pipeline based partly on two platform technologies: an eHealth platform designed to monitor a broad range of health parameters, control treatment from inside the body and communicate to the caregiver on distance and a wireless energising platform designed to power remote controlled implants wirelessly through intact skin. Implantica is listed on Nasdaq First North Premier Growth Market (ticker: IMP A SDB). Visit www.implantica.com for further information.
Newsroom
https://www.implantica.com/media/media-kit
Community
https://www.linkedin.com/implantica
https://www.twitter.com/implantica
The following files are available for download:
View original content:https://www.prnewswire.co.uk/news-releases/save-the-date-implantica-capital-markets-day-2023-301905354.html
Ufficio Stampa
PR Newswire (Leggi tutti i comunicati)
209 - 215 Blackfriars Road
LONDON United Kingdom
